A. Irigoyen

发表

Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers

Octavio Caba, Francisco Manuel Ortuño, Jose Prados, 2017, PloS one.

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

J. Lambea, R. Hitt, D. Isla, 2010, British Journal of Cancer.

Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck

A. Concha, J. Valdivia, A. Irigoyen, 2005 .

Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)

M. Hidalgo, R. Hitt, C. Jara, 2007 .

Phase II study of capecitabine as palliative treatment for patients (p) with squamous head and neck cancer (HNC) with locoregional and/or metastatic relapse after previous platinum-based treatment (PBT): Final results of Spanish Head and Neck Cancer Group (TTCC).

J. Lambea, R. Hitt, D. Isla, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

J. Aparicio, R. López, A. Irigoyen, 2012, Clinical and Translational Oncology.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

C. García-Girón, R. Hitt, C. Jara-Sánchez, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

U. Dafni, D. de Ruysscher, D. Ruysscher, 2019, Lung cancer.

Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC).

R. Hitt, H. Cortés-Funes, A. Irigoyen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transcriptional Profiling of Peripheral Blood in Pancreatic Adenocarcinoma Patients Identifies Diagnostic Biomarkers

P. Álvarez, J. Prados, C. Melguizo, 2014, Digestive Diseases and Sciences.

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

R. Hitt, J. García-Saenz, H. Cortés-Funes, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis Relevance of Serum Cytokines in Pancreatic Cancer

J. Prados, A. Aránega, O. Caba, 2015, BioMed research international.

Serum Cytokine Profile in Patients With Pancreatic Cancer

J. Prados, A. Aránega, Miguel Martín, 2014, Pancreas.

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).

M. Valladares-Ayerbes, F. Rivera, C. Pericay, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of irinotecan as first‐line chemotherapy for patients with advanced colorectal carcinoma

M. Valladares-Ayerbes, A. Irigoyen, P. Diz, 2001, Cancer.

Consensus on the treatment of pancreatic cancer in Spain

M. Hidalgo, J. Tabernero, A. Abad, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.

M. Martín, F. Rivera, R. Pazo-Cid, 2017, European journal of cancer.

A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine.

F. Rivera, C. Pericay, A. Irigoyen, 2010 .

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.

U. Dafni, D. Ruysscher, R. Stahel, 2018 .

Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients.

J. Prados, C. Jiménez-Luna, O. Caba, 2016, Toxicology and applied pharmacology.

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.

J. Carles, J. García-Saenz, R. Mesía, 2016, International journal of radiation oncology, biology, physics.

Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial

U. Dafni, D. Ruysscher, R. Stahel, 2019, Annals of Oncology.

Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group.

F. Rivera, M. Benavides, E. Aranda, 2014 .

A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN.

J. García-Saenz, R. Mesía, A. Irigoyen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

C. García-Girón, R. Hitt, C. Jara-Sánchez, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

R. Hitt, J. García-Saenz, A. Irigoyen, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

J. Carles, J. García-Saenz, R. Mesía, 2016, International journal of radiation oncology, biology, physics.

M. Martín, F. Rivera, R. Pazo-Cid, 2017, European journal of cancer.